Cargando…

Comparing the Efficacy of Drug Regimens for Pulmonary Tuberculosis: Meta-analysis of Endpoints in Early-Phase Clinical Trials

BACKGROUND: A systematic review of early clinical outcomes in tuberculosis was undertaken to determine ranking of efficacy of drugs and combinations, define variability of these measures on different endpoints, and to establish the relationships between them. METHODS: Studies were identified by sear...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bonnett, Laura J, Ken-Dror, Gie, Koh, Gavin C K W, Davies, Geraint R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Articles and Commentaries
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850317/ https://www.ncbi.nlm.nih.gov/pubmed/28402396 http://dx.doi.org/10.1093/cid/cix247

Ejemplares similares

Quality of reporting of outcomes in phase III studies of pulmonary tuberculosis: a systematic review
por: Bonnett, Laura Jayne, et al.
Publicado: (2018)

Reported outcomes in phase II studies of newly-diagnosed pulmonary tuberculosis
por: Bonnett, Laura J, et al.
Publicado: (2015)

Quality of outcome reporting in phase II studies in pulmonary tuberculosis
por: Bonnett, Laura Jayne, et al.
Publicado: (2015)

A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis
por: Imperial, Marjorie Z., et al.
Publicado: (2018)

Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies
por: Blumenthal, Gideon M., et al.
Publicado: (2017)

Endpoints used in phase III randomized controlled trials of treatment options for COVID-19
por: Desai, Aakash, et al.
Publicado: (2020)

Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed
por: Denton, Christopher P, et al.
Publicado: (2011)

Endpoints and viewpoints on spatial neglect
por: McIntosh, Robert D., et al.
Publicado: (2022)

The impact of inclusion, dose and duration of pyrazinamide (PZA) on efficacy and safety outcomes in tuberculosis: systematic review and meta-analysis protocol
por: Millard, James D., et al.
Publicado: (2019)

Pitfall in the Design and Analysis of Comparative Oncology Trials With a Time-to-Event Endpoint and Recommendations
por: McCaw, Zachary R, et al.
Publicado: (2022)

Publisher Correction: A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis
por: Imperial, Marjorie Z., et al.
Publicado: (2018)

A systematic review of endpoint definitions in late phase pulmonary tuberculosis therapeutic trials
por: Hills, N. K., et al.
Publicado: (2021)

The optimal endpoint of resuscitation in trauma patients
por: Marik, Paul E
Publicado: (2003)

The Search for Surrogate Endpoints in Trials in Diffuse Large B‐Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project
por: Sargent, Daniel J., et al.
Publicado: (2017)

Is critical care ready for an economic surrogate endpoint?
por: Wilcox, M Elizabeth, et al.
Publicado: (2015)

Suicidal thinking as a valuable clinical endpoint
por: Kleiman, Evan M.
Publicado: (2020)

Shortened treatment regimens versus the standard regimen for drug‐sensitive pulmonary tuberculosis
por: Grace, Angeline G, et al.
Publicado: (2019)

Optimizing tuberculosis treatment efficacy: Comparing the standard regimen with Moxifloxacin-containing regimens
por: Budak, Maral, et al.
Publicado: (2023)

Composite endpoints for malaria case-management: not simplifying the picture?
por: Cairns, Matthew E, et al.
Publicado: (2014)

Surrogate endpoints in trials: a call for better reporting
por: Ciani, Oriana, et al.
Publicado: (2022)

Is the efficacy of psychopharmacological drugs comparable to the efficacy of general medicine medication?
por: Seemüller, Florian, et al.
Publicado: (2012)

Medication Therapy Management Versus Drug Regimen Review
por: Summers, Kent H.
Publicado: (2007)

Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs
por: Davies, Geraint, et al.
Publicado: (2019)

Surrogate endpoints and competing risk of death in cardiac arrest research
por: McCredie, Victoria A., et al.
Publicado: (2016)

Bridging the Gap Between RCTs and RWE Through Endpoint Selection
por: LoCasale, Robert J., et al.
Publicado: (2020)

Endpoints for geroscience clinical trials: health outcomes, biomarkers, and biologic age
por: Cummings, Steven R., et al.
Publicado: (2022)

Tuberculosis and pulmonary hypertension: Commentary
por: Verma, Ajay Kumar
Publicado: (2016)

Pharmacodynamic Modeling of Bacillary Elimination Rates and Detection of Bacterial Lipid Bodies in Sputum to Predict and Understand Outcomes in Treatment of Pulmonary Tuberculosis
por: Sloan, Derek J., et al.
Publicado: (2015)

Need for better reporting of trials with surrogate endpoints: SPIRIT|CONSORT-SURROGATE extensions
por: Ciani, Oriana, et al.
Publicado: (2022)

Chronic obstructive pulmonary disease and tuberculosis
por: Jain, Nirmal Kumar
Publicado: (2017)

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study
por: van Wyk, Jean, et al.
Publicado: (2020)

Methods for safety and endpoint ascertainment: identification of adverse events through scrutiny of negatively adjudicated events
por: Fanaroff, Alexander C., et al.
Publicado: (2020)

Non-inferiority versus superiority drug claims: the (not so) subtle distinction
por: Ganju, Jitendra, et al.
Publicado: (2017)

The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis
por: Svensson, Elin M, et al.
Publicado: (2018)

A randomised controlled trial is not a pilot trial simply because it uses a surrogate endpoint
por: Campbell, M. J., et al.
Publicado: (2018)

Identifying the levels of pro-fibrotic cytokines in pulmonary tuberculosis
por: Verma, Ajay Kumar
Publicado: (2018)

Pharmacokinetics, Safety, and Efficacy of an Allometric Miltefosine Regimen for the Treatment of Visceral Leishmaniasis in Eastern African Children: An Open-label, Phase II Clinical Trial
por: Mbui, Jane, et al.
Publicado: (2019)

Drug-resistant tuberculosis: is India ready for the challenge?
por: Chatterjee, Soumya, et al.
Publicado: (2018)

Development of drugs for celiac disease: review of endpoints for Phase 2 and 3 trials
por: Gottlieb, Klaus, et al.
Publicado: (2015)

Transcriptomic Signatures Predict Regulators of Drug Synergy and Clinical Regimen Efficacy against Tuberculosis
por: Ma, Shuyi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_n1molscj1imhuiub2hm2d39vpd